Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박찬혁 | - |
dc.date.accessioned | 2019-11-27T20:44:20Z | - |
dc.date.available | 2019-11-27T20:44:20Z | - |
dc.date.issued | 2017-07 | - |
dc.identifier.citation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v. 46, no. 2, page. 106-114 | en_US |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.issn | 1365-2036 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14130 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/115004 | - |
dc.description.abstract | Background: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. Aim: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. Methods: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori." Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies. Results: Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively. The eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan-based triple therapy [95% CI]= 0.69 [0.23-2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]= 1.02 [0.78-1.34]). Conclusions: The vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI-based triple therapy. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events. | en_US |
dc.description.sponsorship | This work was supported by the research fund of Hanyang University (HY-2016) | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | WILEY | en_US |
dc.subject | COMPETITIVE ACID BLOCKER | en_US |
dc.subject | PROTON PUMP INHIBITORS | en_US |
dc.subject | RANDOMIZED CLINICAL-TRIAL | en_US |
dc.subject | VS. LANSOPRAZOLE | en_US |
dc.subject | GUIDELINES | en_US |
dc.subject | RESISTANCE | en_US |
dc.subject | 1ST-LINE | en_US |
dc.subject | KOREA | en_US |
dc.subject | ESOMEPRAZOLE | en_US |
dc.title | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 46 | - |
dc.identifier.doi | 10.1111/apt.14130 | - |
dc.relation.page | 106-114 | - |
dc.relation.journal | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.contributor.googleauthor | Jung, Y. S. | - |
dc.contributor.googleauthor | Kim, E. H. | - |
dc.contributor.googleauthor | Park, C. H. | - |
dc.relation.code | 2017002174 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | chan100 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.